Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals director Ian Clark resigns from board effective July 22, 2026

Neutral Impact 2 of 5 leadership Written later

Corvus Pharmaceuticals said director Ian T. Clark gave notice on July 21, 2026 that he will resign from its board, effective July 22, 2026. The company thanked him for more than nine years of board service, and the filing gives no replacement or reason for the departure.

Key points

  • Ian T. Clark delivered resignation notice on July 21, 2026.
  • Resignation is effective July 22, 2026.
  • Clark served on the board for over nine years, according to the company.

The filing

CompanyCorvus Pharmaceuticals, Inc. (CRVS)
Form8-K, current report
Filed with the SECJul 22, 2026, 4:02 PM ET
Accession number0001104659-26-085790

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.